Common antibiotic may combat dry eye disease

December 23, 2013

Meibomian gland dysfunction (MGD) is the leading cause of dry eye disease, which affects tens of millions of Americans. However, there is no FDA-approved treatment for MGD. Researchers from the Schepens Eye Research Institute/Massachusetts Eye and Ear and Harvard Medical School have just identified a potential therapy.

"We discovered that azithromycin, an antibiotic, can directly stimulate the function of human meibomian gland epithelial cells," said First Author Yang Liu, M.D., a postdoctoral fellow at Schepens Eye Research Institute and Harvard Medical School. Their finding is outlined in a Research Letter that was published Online First in JAMA Ophthalmology.

This finding is very clinically significant, because topical azithromycin is the most commonly prescribed MGD treatment in the USA, but its use is 'off-label,' which means the drug's efficacy has not yet been evaluated and approved by the Food and Drug Administration for patients with MGD. This antibiotic has been presumed to be effective because of its anti-inflammatory and anti-bacterial actions, which may suppress the MGD-associated conjunctival inflammation (i.e. posterior blepharitis) and growth of lid bacteria.

"We hypothesized that azithromycin could act directly on human meibomian gland epithelial cells to stimulate their differentiation, enhance the quality and quantity of their lipid production, and promote their holocrine secretion. Our results support this hypothesis," said Senior Author David A. Sullivan, Ph.D., Senior Scientist and Margaret S. Sinon Scholar in Ocular Surface Research, Schepens Eye Research Institute and Associate Professor of Ophthalmology, Harvard Medical School.

The findings in this study may help lead to broader use of topical azithromycin as an FDA-approved, 'on-label' treatment to ameliorate the pathophysiology of MGD and its associated evaporative .

Explore further: Ranibizumab may prevent retinal detachment side effect

More information: Yang Liu, M.D.; Wendy R. Kam, M.S.; Juan Ding, Ph.D.; and David A. Sullivan, Ph.D. JAMA Ophthalmology archopht.jamanetwork.com/article.aspx?articleid=1792853

Related Stories

Ranibizumab may prevent retinal detachment side effect

April 9, 2013

Proliferative vitreoretinopathy (PVR), or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, ...

Recommended for you

Zika can harm babies' vision, too

April 18, 2017

(HealthDay)—Although Zika virus is most well-known for the devastating neurological damage it can cause in the womb, a new study reports that some babies infected with Zika also may have lifelong vision impairment.

Scientists grow eye cells to fix corneas

April 17, 2017

A Stanford University research team has created a potentially powerful new way to fix damaged corneas—a major source of vision problems and blindness.

Everyone has different 'bad spots' in their vision

April 10, 2017

The ability to distinguish objects in peripheral vision varies significantly between individuals, finds new research from UCL, Paris Descartes University and Dartmouth College, USA. For example, some people are better at ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.